Seeking AlphaCodex · 实盘不做把握 5/10
北京时间·🕒 发布 22:27:00时区推断·⟳ 抓取 22:29:06·⚡ 决策 07-23 22:35:56 +6m50s·95.9 天前
Molina二季度盈利虽超预期但Marketplace医疗成本显著高于预期，拖累管理式医疗股盘中下跌
Molina二季度调整后EPS为1.51美元、收入108.74亿美元，均小幅高于预期，且公司将2026年调整后EPS指引上调至至少5.25美元。
📄 原文Seeking Alpha↗ 原文
Molina tumbles despite Q2 beat amid high medical expenses
Despite reporting better-than-expected financials, Molina Healthcare (MOH) traded lower in the morning hours on Thursda…
不做 Molina Healthcare（MOH.US）
财报为正负混合：Marketplace成本超预期偏空，但全年EPS指引上调且Medicaid/Medicare有抵消；MOH盘中已跌11.24%，Futu未返回可借券库存确认，不满足做空红线，不做。
不做 Centene（CNC.US）
仅为MOH Marketplace成本压力的同业读出，CNC自身Q2尚未披露且盘中已跌2.72%，不是当前事件直接确认的公司级净损害，不做。
不做 Oscar Health（OSCR.US）
OSCR虽有Marketplace read-across，但当前信号未披露其自身成本或会员数据，且盘中已同向下跌，缺少可执行同向edge，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
消息传播链
- 公司发布二季度业绩，披露调整后EPS 1.51美元、收入108.74亿美元、综合MCR 92.2%，并说明Marketplace MCR高于公司预期。
- 媒体转述Bloomberg卖方关注Marketplace医疗成本，称MOH盘中跌约11%，CNC和OSCR也承压。市场反应:MOH.US约-11%，CNC.US约-3%，OSCR.US小幅下跌。
- 2026-07-23 14:34 UTC市场反应Futu行情非一手实时行情显示MOH.US报196.82美元、跌11.24%，负面已被快速交易。市场反应:MOH.US -11.24%，CNC.US -2.72%，OSCR.US -1.08%。
关键理由
- Molina二季度调整后EPS为1.51美元、收入108.74亿美元，均小幅高于预期，且公司将2026年调整后EPS指引上调至至少5.25美元。
- 负面增量集中在Marketplace业务：MCR升至88.9%，高于市场预期83.9%，公司称Marketplace拖累全年EPS约1.50美元，直接压低2027盈利能力讨论。
- 当前MOH.US盘中已跌约11%，CNC.US和OSCR.US也已同向下跌，事件已被即时重定价；同时主公司财报仍有上调指引的正面抵消，空头edge不够干净。
主要风险
- 若后续电话会或卖方进一步确认Marketplace问题外溢到2027年，MOH和ACA Marketplace敞口较高的同业仍可能继续承压。
- 公司同时上调全年EPS指引且称Medicaid成本趋势趋稳，追空容易被管理层2027修复叙事反抽。
反向证据
- 做空前查反向 · 来源 web · 日期 2026-07-22 · 影响 weakens
公司官方称Medicaid成本趋势稳定、Medicare好于预期，并上调2026年调整后EPS指引至至少5.25美元，削弱追空确定性。
检索:Molina Healthcare Q2 2026 earnings guidance raised Medicaid stabilized Marketplace MCR counter evidence 原文 ↗ - 做空前查反向 · 来源 kb_search · 日期 2026-07-23 · 影响 weakens
内部库命中摩根士丹利当日研报，标题指向北美HIX业务喜忧参半，说明该分歧已进入卖方讨论而非低扩散新信息。
检索:Molina Healthcare Q2 2026 medical care ratio Marketplace MCR 2027 earnings power 原文 ↗
工具调用 · 历史记录,结果未知(3 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
- kb_search · 结果未知
原文全文
展开原文 · 1,710 字
Despite reporting better-than-expected financials, Molina Healthcare (MOH) traded lower in the morning hours on Thursday, leading a decline among its managed care peers as analysts focused on its medical costs that exceeded estimates.
Molina (MOH) fell ~11%, marking its biggest intraday decline since February, while shares of competitors Centene (CNC) and Oscar Health (OSCR), which are yet to report Q2 results, also came under pressure.
On Thursday, Long Beach, California-based Molina (MOH) recorded $1.51 of adjusted EPS for Q2 on $10.9B in revenue, indicating a ~72% YoY and ~5% YoY decline, respectively, but exceeding the consensus by $0.11 and $90M.
The company’s overall medical care ratio reached 92.2% compared to 90.4% in the prior-year period and 92.5% projected by analysts, according to Bloomberg data.
However, its Marketplace business saw a spike in medical costs with MCR reaching 88.9% from 85.4% in Q2 2025 and surpassing 83.9% in the consensus, while membership in the unit also dropped to 230K with nearly a 60% decline from the prior year's period.
Baird analyst Michael Ha, with a Neutral rating on MOH, said headwinds in the Marketplace business remain a matter of concern. “We believe the primary focus of the MOH investment debate continues to be 2027 earnings power,” Bloomberg reported, quoting Ha.
Jefferies analyst David Windley, with a Hold rating, noted multiple issues in the company’s Marketplace business, which he said brings its viability into question. Molina’s (MOH) Marketplace enrollees “also declined slightly more than our estimates, meaning the (40%) organic attrition assumption seems likely, despite the overall market attriting more slowly," the analyst added.
Molina (MOH) fell ~11%, marking its biggest intraday decline since February, while shares of competitors Centene (CNC) and Oscar Health (OSCR), which are yet to report Q2 results, also came under pressure.
On Thursday, Long Beach, California-based Molina (MOH) recorded $1.51 of adjusted EPS for Q2 on $10.9B in revenue, indicating a ~72% YoY and ~5% YoY decline, respectively, but exceeding the consensus by $0.11 and $90M.
The company’s overall medical care ratio reached 92.2% compared to 90.4% in the prior-year period and 92.5% projected by analysts, according to Bloomberg data.
However, its Marketplace business saw a spike in medical costs with MCR reaching 88.9% from 85.4% in Q2 2025 and surpassing 83.9% in the consensus, while membership in the unit also dropped to 230K with nearly a 60% decline from the prior year's period.
Baird analyst Michael Ha, with a Neutral rating on MOH, said headwinds in the Marketplace business remain a matter of concern. “We believe the primary focus of the MOH investment debate continues to be 2027 earnings power,” Bloomberg reported, quoting Ha.
Jefferies analyst David Windley, with a Hold rating, noted multiple issues in the company’s Marketplace business, which he said brings its viability into question. Molina’s (MOH) Marketplace enrollees “also declined slightly more than our estimates, meaning the (40%) organic attrition assumption seems likely, despite the overall market attriting more slowly," the analyst added.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。